Switzerland based online trading firm Swissquote has announced a new trading certificate, which enables investors to actively support companies in their fight against COVID-19.

Available to investors in the GCC through the firm’s licensed UAE subsidiary Swissquote MEA Ltd, Swissquote’s Pharma Opportunity Certificate allows its clients to invest in a comprehensive and diversified portfolio of the world’s leading pharmaceutical and biotech companies that are seeking solutions to put an end to the pandemic.

Commenting on the announcement, Dino Ibric, Vice Director at Swissquote MEA said:

“2020 will undoubtedly go down in history as the year of COVID-19. What initially seemed to be a small epidemic limited to China has since spread out across the entire globe, seriously affecting societies and economies, and dramatically impacting our way of life. While most of us feel powerless in the face of all these events, our clients now have the opportunity to support the fight against the Coronavirus by investing in companies that are researching the solutions for it.”

Swissquote stated that there has been an unprecedented eruption of global pharmaceutical research and development related to COVID-19. More than 330 clinical studies and 80 vaccine candidates are currently under review, while Big pharma and biotech companies across the world are working to find a drug to manage or defeat COVID-19. With the Pharma Opportunity Certificate, Swissquote said that its customers can now invest in the performance of companies that are actively working on medicines to combat the Coronavirus by developing vaccines or treatments.

The certificate allows for diversification of investments and is traded on the SIX Swiss Exchange with flat transaction costs for Swisssquote MEA clients.

Based in the Dubai International Financial Centre (DIFC), Swissquote MEA Ltd holds a category 3A license from the Dubai Financial Services Authority (DFSA).